Paul G. Allen Frontiers Group [to 9 Mar 2019]
No new digest content identified.

BMGF – Gates Foundation [to 9 Mar 2019]
No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 9 Mar 2019]
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

CARB-X [to 9 Mar 2019]
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
CARB-X funds ContraFect to develop a new class of antibiotics to treat serious infections caused by Gram-negative ESKAPE superbugs
ContraFect’s new class of phage-encoded lytic agents called ‘amurins’ aims to treat the deadliest drug-resistant Gram-negative pathogens

CEPI – Coalition for Epidemic Preparedness Innovations  [to 9 Mar 2019]
07 Mar 2019
Nipah – The Next Global Pandemic?
Last year, Stanford epidemiologist and Nipah expert Stephen Luby, a scientist who forms part of the team working on our University of Tokyo partnership to develop a Nipah vaccine, spoke about the risks posed by the 2018 Nipah virus outbreak and potential interventions to halt its spread.
[See Milestones above for an exchange of letters between MSF and CEPI.
EDCTP    [to 9 Mar 2019]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.

Emory Vaccine Center    [to 9 Mar 2019]
No new digest content identified.

European Medicines Agency  [to 9 Mar 2019]
News and press releases
No new digest content identified.

European Vaccine Initiative  [to 9 Mar 2019]
Latest news
Launch of SENET – the Sino-European Health NETworking Hub
05 March 2019
EVI supports new EC-funded project that aims to strengthen international research and innovation cooperation between China and the EU

FDA [to 9 Mar 2019]
No new digest content identified.
[See Milestones above for coverage of Commissioner Scott Gottlieb’s announced resignation.]

Fondation Merieux [to 9 Mar 2019]
No new digest content identified.

Gavi [to 9 Mar 2019]
Latest News
Gavi signs new cooperation agreement with Japan International Cooperation Agency
05 March 2019
Geneva, 5 March 2019 – Gavi, the Vaccine Alliance and the Japan International Cooperation Agency (JICA) will work together to boost vaccine coverage and improve health systems in the world’s poorest countries following the signing of a new Memorandum of Cooperation…
“Japan has been a key Gavi supporter since 2011, helping us to vaccinate millions of children against some of the world’s deadliest diseases,” said Dr Berkley. “I’m delighted to sign this new agreement with Dr Toda, which will ensure we continue to work together to improve the health of children worldwide for years to come.”
The Memorandum of Cooperation commits both Gavi and JICA to collaborate to enhance information sharing and improve the use of innovation in areas including modernisation of the cold chain, digital identification and the digitalisation of maternal and child health and immunisation data.
The two organisations will also promote the dissemination of integrated records, such as a maternal and child health handbook, and explore ways to promote the sustainability of immunisation programmes through technical cooperation and the use of innovative financing instruments.
The Japan International Cooperation Agency (JICA) coordinates Japan’s official development assistance (ODA).

GHIT Fund [to 9 Mar 2019]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
No new digest content identified.

Global Fund [to 9 Mar 2019]
No new digest content identified.

Hilleman Laboratories [to 9 Mar 2019]
No new digest content identified.

Human Vaccines Project [to 9 Mar 2019]
No new digest content identified.

IAVI [to 9 Mar 2019]
No new digest content identified.

No new digest content identified.

IVAC [to 9 Mar 2019]
No new digest content identified.

IVI   [to 9 Mar 2019]
IVI News & Announcements
IVI receives $3.2 million grant to support TCV effectiveness studies in West Africa
SEOUL, Korea — The International Vaccine Institute (IVI) has been awarded a $3,238,974 grant from the Bill & Melinda Gates Foundation to provide technical assistance support for studies to measure the effectiveness of typhoid conjugate vaccine (TCV) in West Africa.

This grant comes after a consortium, led by the University of Cambridge, Department of Medicine (UCAM), was awarded a €13 million grant from the European and Developing Countries Clinical Trials Partnership (EDCTP). This EDCTP “THECA” grant will fund the assessment of the effectiveness of a novel TCV through two clinical studies: a cluster-randomized trial in Ghana and a mass vaccination campaign with a nested case-control effectiveness component in the Democratic Republic of the Congo (DRC).

IVI is an integral part of the consortium with partners from Ghana, the DRC, Belgium, Bangladesh, Madagascar, Burkina Faso, the United Kingdom, and the United States. The technical support to THECA, funded by this grant from the Bill & Melinda Gates Foundation, will continue through May 2023.

“Typhoid is a poverty-associated infectious disease. It strikes the impoverished and frequently occurs in low-income settings where there is a lack of access to clean water and where sanitation and hygiene are poor. Infants and young children are at higher risk,” said Mr. Justin Im, Associate Research Scientist in the Epidemiology and Outcomes Unit. “IVI is proud to be a member of the consortium that will evaluate the effectiveness of the novel TCV.”…
JEE Alliance  [to 9 Mar 2019]
Selected News and Events
Mali – A Multi-sectoral and Multi-stakeholder Cooperation Success Story
Disease outbreaks continue to occur in Mali and the ongoing security crisis highlights the importance of a comprehensive national framework for health security. Recognizing the need for cooperation…
 MSF/Médecins Sans Frontières  [to 9 Mar 2019]
Selected News; Project Updates, Reports [as presented on website]
Democratic Republic of Congo
Ebola response failing to gain the upper hand on the epidemic
Press Release 7 Mar 2019
[See DRC Ebola above for detail]
Women’s health
Unsafe abortion: a forgotten emergency
Project Update 4 Mar 2019
NIH  [to 9 Mar 2019]

News Releases
Researchers report high rate of viral suppression among people new to HIV care
March 7, 2019 — NIH-funded study reflects advances in HIV care, but gaps remain.

Tuberculosis diagnosis in people with HIV increases risk of death within 10 years
March 6, 2019 — NIH-supported analysis identified elevated mortality in large Latin American cohort.

Study finds Ebola survivors in Liberia face ongoing health issues
March 6, 2019 — Report compares health outcomes in survivors and contacts during their first year of study participation.

HIV prevention study finds universal “test and treat” approach can reduce new infections
March 5, 2019 — NIH-sponsored trial suggests home-based HIV testing and referral to care works at population level.
PATH  [to 9 Mar 2019]
No new digest content identified.
Sabin Vaccine Institute  [to 9 Mar 2019]

Tuesday, March 5, 2019

Sabin Statement on Senate HELP Committee Hearing on What is Driving Preventable Disease Outbreaks

WASHINGTON, D.C. – Today, the Senate Health, Education, Labor, and Pensions (HELP) Committee conducted a hearing on rising rates of vaccine hesitancy causing preventable disease outbreaks across the country – such as the ongoing outbreaks in Washington, Illinois and New York.

Sabin applauds Senate HELP Committee Chair Lamar Alexander (R-TN) and Ranking Member Patty Murray (D-WA) for providing a forum for public health experts to share their expertise and stories on the importance of vaccination to public health.

“The science is clear – vaccines are proven to work. Their introduction is one of the greatest public health innovations in the 20th century, though millions around the globe are still impacted by vaccine-preventable diseases. We commend the Senate HELP Committee for raising this issue to a national platform and addressing the surge of false information found on social media,” said Bruce Gellin, M.D., M.P.H., Sabin’s president of Global Immunization.
UNAIDS [to 9 Mar 2019]
Selected Press Releases/Reports/Statements
8 March 2019
Africa — Achieving health coverage without compromising on quality
8 March 2019
People living with HIV face major challenges in Zimbabwe
7 March 2019
Turning words into action for gender equality
UNICEF  [to 9 Mar 2019]
Selected Press Releases/Reports/Statements
No new digest content identified.
Vaccine Confidence Project  [to 9 Mar 2019]
No new digest content identified.
Vaccine Education Center – Children’s Hospital of Philadelphia  [to 9 Mar 2019]
No new digest content identified.
Wellcome Trust  [to 9 Mar 2019]
News | 6 March 2019
Wellcome pledges new funds to tackle Ebola outbreak – but more is needed to prevent catastrophe
Wellcome is making £2 million available to the WHO and government of DRC, to support vaccine research as part of the emergency response to the Ebola outbreak.
[See DRC-Ebola above for more detail]
The Wistar Institute   [to 9 Mar 2019]
Press Release  Mar. 6, 2019
New Small Molecule Inhibitors Show Potential for Treatment of Epstein-Barr Virus-Associated Cancers
First-in-class pharmacological inhibitors of the EBNA1 viral protein are effective at inhibiting tumor growth in preclinical models.
World Organisation for Animal Health (OIE) [to 9 Mar 2019]
No new digest content identified.


BIO [to 9 Mar 2019]
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 9 Mar 2019]
No new digest content identified.

IFPMA [to 9 Mar 2019]
No new digest content identified.

PhRMA [to 9 Mar 2019]
No new digest content identified.